113 related articles for article (PubMed ID: 14612031)
1. Effect of HMG-CoA reductase inhibitors on reduction of panel reactivity.
Ossareh S; Ghorbani G; Ghods AJ
Transplant Proc; 2003 Nov; 35(7):2592-3. PubMed ID: 14612031
[No Abstract] [Full Text] [Related]
2. Re: Lovastatin for reduction of leptin in nondialysis patients with type 2 diabetic nephropathy.
Ahmadi F; Mohebi-Nejad A
Iran J Kidney Dis; 2014 Jul; 8(4):344-5. PubMed ID: 25001144
[No Abstract] [Full Text] [Related]
3. Effect of lovastatin, an HMG CoA reductase inhibitor, on acute renal allograft rejection.
Sahu K; Sharma R; Gupta A; Gulati S; Agarwal D; Kumar A; Bhandari M
Clin Transplant; 2001 Jun; 15(3):173-5. PubMed ID: 11389707
[TBL] [Abstract][Full Text] [Related]
4. Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors.
Tobert JA
Nat Rev Drug Discov; 2003 Jul; 2(7):517-26. PubMed ID: 12815379
[TBL] [Abstract][Full Text] [Related]
5. Residual effects of lovastatin and simvastatin on urinary mevalonate excretions in patients with familial hypercholesterolemia.
Pappu AS; Bacon SP; Illingworth DR
J Lab Clin Med; 2003 Apr; 141(4):250-6. PubMed ID: 12677170
[TBL] [Abstract][Full Text] [Related]
6. HMG-CoA reductase inhibitors decrease CD11b expression and CD11b-dependent adhesion of monocytes to endothelium and reduce increased adhesiveness of monocytes isolated from patients with hypercholesterolemia.
Weber C; Erl W; Weber KS; Weber PC
J Am Coll Cardiol; 1997 Nov; 30(5):1212-7. PubMed ID: 9350917
[TBL] [Abstract][Full Text] [Related]
7. Effects of nicotinic acid and lovastatin in combination with cholestyramine in renal transplant patients.
Lal SM; Katyal A
Mo Med; 2002; 99(10):580-4. PubMed ID: 12534147
[TBL] [Abstract][Full Text] [Related]
8. Effects of lipids on the pathogenesis of progressive renal failure: role of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in the prevention of glomerulosclerosis.
Guijarro C; Keane WF
Miner Electrolyte Metab; 1996; 22(1-3):147-52. PubMed ID: 8676808
[TBL] [Abstract][Full Text] [Related]
9. Lipid-lowering long-term effects of six different statins in hypercholesterolemic renal transplant patients under cyclosporine immunosuppression.
Martínez-Castelao A; Grinyó JM; Gil-Vernet S; Serón D; Castiñeiras MJ; Ramos R; Alsina J
Transplant Proc; 2002 Feb; 34(1):398-400. PubMed ID: 11959343
[No Abstract] [Full Text] [Related]
10. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences.
Lennernäs H; Fager G
Clin Pharmacokinet; 1997 May; 32(5):403-25. PubMed ID: 9160173
[TBL] [Abstract][Full Text] [Related]
11. Comparative effects of two HMG-CoA reductase inhibitors (lovastatin and pravastatin) on serum lipids and lipoproteins.
Richter WO; Jacob BG; Schwandt P
Int J Tissue React; 1991; 13(2):107-10. PubMed ID: 1955291
[TBL] [Abstract][Full Text] [Related]
12. HMG-CoA reductase inhibitor treatment in renal insufficiency.
Wanner C
Nephrol Dial Transplant; 1996 Oct; 11(10):1951-2. PubMed ID: 8918704
[No Abstract] [Full Text] [Related]
13. Lovastatin and other HMG-CoA reductase inhibitors.
Frishman WH; Zimetbaum P; Nadelmann J
J Clin Pharmacol; 1989 Nov; 29(11):975-82. PubMed ID: 2689473
[No Abstract] [Full Text] [Related]
14. HMG CoA reductase inhibitors and quality of life.
Downs JR; Oster G; Santanello NC
JAMA; 1993 Jun 23-30; 269(24):3107-8. PubMed ID: 8505809
[No Abstract] [Full Text] [Related]
15. Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia.
Hsu I; Spinler SA; Johnson NE
Ann Pharmacother; 1995; 29(7-8):743-59. PubMed ID: 8520093
[TBL] [Abstract][Full Text] [Related]
16. Successful use of an HMG-CoA reductase inhibitor as adjunctive therapy in the management of refractory bile leak complicating laparoscopic cholecystectomy.
Rabine J; Jones MP
Am J Gastroenterol; 1998 Dec; 93(12):2602-3. PubMed ID: 9860442
[No Abstract] [Full Text] [Related]
17. Comparison of a statin vs. hypolipemic diet on the oxidant status in hemodialyzed patients with chronic renal failure.
Mastalerz-Migas A; Reksa D; Pokorski M; Steciwko A; Muszyńska A; Bunio A; Drobnik J; Pokorna-Kałwak D
J Physiol Pharmacol; 2007 Nov; 58 Suppl 5(Pt 1):363-70. PubMed ID: 18204148
[TBL] [Abstract][Full Text] [Related]
18. Mechanism of action and biological profile of HMG CoA reductase inhibitors. A new therapeutic alternative.
Slater EE; MacDonald JS
Drugs; 1988; 36 Suppl 3():72-82. PubMed ID: 3076125
[TBL] [Abstract][Full Text] [Related]
19. Serum levels of lipoprotein(a) and homocysteine in patients on hemodialysis who take hydroxymethylglutaryl-CoA reductase inhibitors, vitamin B6, and folic acid.
Shojaei MH; Djalali M; Siassi F; Khatami MR; Boroumand MA; Eshragian MR
Iran J Kidney Dis; 2009 Jul; 3(3):141-4. PubMed ID: 19617662
[TBL] [Abstract][Full Text] [Related]
20. Lovastatin for reduction of leptin in nondialysis patients with type 2 diabetic nephropathy.
Gholamin S; Razavi SM; Taghavi-Garmestani SM; Ghorbanihaghjo A; Rashtchizadeh N; Safa J; Vatankhah AM; Azizi T; Argani H
Iran J Kidney Dis; 2014 May; 8(3):201-6. PubMed ID: 24878942
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
